What is the 13F Pro Quality Score for RNTX?

13F Pro ranks Rein Therapeutics, Inc. (RNTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RNTX's current score at https://13fpro.ai/research/RNTX (free sign-up required for the full ranking).

Where does 13F Pro source RNTX data?

All Rein Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Rein Therapeutics, Inc. files with the SEC under CIK 1420565. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RNTX in?

Rein Therapeutics, Inc. (RNTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RNTX research updated on 13F Pro?

RNTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Rein Therapeutics, Inc.(RNTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1420565 RNTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RNTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Rein Therapeutics, Inc. (RNTX), a Healthcare sector company. RNTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Rein Therapeutics, Inc. reports net income of $-5.8M, free cash flow of $-3.4M. Top institutional holders of RNTX by reported 13-F value include Voss Capital,, BIOS Capital Management,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. RNTX trades on the Nasdaq exchange and files with the SEC under CIK 1420565. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Rein Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-5.8M

Free Cash Flow

Q1 2026

$-3.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2025

FY22 $0.00FY23 $0.00FY24 $0.00FY25 $0.00

Net Income

+20.7% YoY

$-49.9MFY 2025

FY22 $-27.3MFY23 $-15.7MFY24 $-62.9MFY25 $-49.9M

Operating Income

+22.2% YoY

$-50.6MFY 2025

FY22 $-27.6MFY23 $-16.3MFY24 $-65.1MFY25 $-50.6M

EPS (Diluted)

+44.2% YoY

$-1.96FY 2025

FY22 $-6.02FY23 $-3.42FY24 $-3.51FY25 $-1.96

Total Assets

-61.2% YoY

$24.2MFY 2025

FY22 $22.0MFY23 $106.0MFY24 $62.2MFY25 $24.2M

Op. Cash Flow

+13.1% YoY

$-19.4MFY 2025

FY22 $-24.9MFY23 $-19.8MFY24 $-22.3MFY25 $-19.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2020	FY 2019
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	$-49.9M +20.7%	$-62.9M -299.7%	$-15.7M +42.4%	$-27.3M +0.0%	$-27.3M +6.9%	$-29.4M
Operating Income	$-50.6M +22.2%	$-65.1M -300.0%	$-16.3M +41.1%	$-27.6M -34.9%	$-20.5M +31.6%	$-30.0M
EPS (Diluted)	$-1.96 +44.2%	$-3.51 -2.6%	$-3.42 +43.2%	$-6.02	—	—
Total Assets	$24.2M -61.2%	$62.2M -41.3%	$106.0M +381.7%	$22.0M +34.7%	$16.3M -38.3%	$26.5M
Operating Cash Flow	$-19.4M +13.1%	$-22.3M -12.5%	$-19.8M +20.3%	$-24.9M -21.4%	$-20.5M +22.7%	$-26.5M

AI Insight: RNTX Financial Trends

Pre-revenue biotech burning equity to fund operations; cash runway appears constrained after Q4 2025 impairment.

• Revenue remains zero across all periods. Q4 2024 and Q4 2025 show large non-operating charges (~$35M+ net losses). Quarterly operating cash burn has improved from $-8M (Q2 2024) to $-3M (Q1 2026).

• Equity has declined 78% from $54M (Q4 2024) to $12M (Q1 2026). No debt shown; company is funding losses entirely from shareholder capital.

⚠ Equity runway at current $-3M quarterly burn is <4 quarters. Q4 2025 equity drop of $29M signals potential financing or impairment event requiring immediate monitoring.

⚠ Q4 charges (Q4 2024: $-43M op loss vs. $-6M net; Q4 2025: $-33M op loss vs. $-32M net) suggest writedowns or one-time expenses. Nature and recurrence unknown from P&L alone.

AI Insight: RNTX Ratio Trends

Rein Therapeutics' returns deteriorated sharply in Q1 2026, with ROA plunging to -88.8%, signaling deepening operational distress.

• ROA collapsed from -41.6% in Q3 2025 to -88.8% in Q1 2026, marking the worst quarterly return on assets in the dataset.

• ROE and ROIC both swung deeply negative through 2025 (ROE from -44.1% to -56.8%), indicating persistent value destruction.

⚠ Q1 2026 ROA spike to -88.8% suggests either a one-time loss or severe near-term operational setback requiring immediate disclosure review.

⚠ Absence of profitability metrics (OpMargin, NPM) across all periods indicates sustained pre-revenue or heavy R&D burn phase.

Get alerted when RNTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Rein Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RNTX

Voss Capital, LP
$5.7M4,388,362 sh
BIOS Capital Management, LP
$2.6M1,982,375 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.3M998,521 sh
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO
$665.1K511,610 sh
Cable Car Capital, LP
$546.0K420,000 sh
Prosight Management, LP
$535.1K411,600 sh
Sigma Planning Corp
$453.3K348,677 sh
GEODE CAPITAL MANAGEMENT, LLC
$448.2K344,690 sh
Texas Capital Bank Wealth Management Services Inc
$355.7K273,625 sh
GAGNON SECURITIES LLC
$311.4K239,520 sh

Fund	Value	Shares
Voss Capital, LP	$5.7M	4,388,362
BIOS Capital Management, LP	$2.6M	1,982,375
VANGUARD CAPITAL MANAGEMENT LLC	$1.3M	998,521
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO	$665.1K	511,610
Cable Car Capital, LP	$546.0K	420,000
Prosight Management, LP	$535.1K	411,600
Sigma Planning Corp	$453.3K	348,677
GEODE CAPITAL MANAGEMENT, LLC	$448.2K	344,690
Texas Capital Bank Wealth Management Services Inc	$355.7K	273,625
GAGNON SECURITIES LLC	$311.4K	239,520

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RNTX on your watchlist

Track score changes the day Rein Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RNTX a good stock to buy?

13F Pro's AI-powered analysis of Rein Therapeutics, Inc. (RNTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNTX are available on the RNTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RNTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Rein Therapeutics, Inc.'s investment landscape.